



PRESS RELEASE

GA Generic Assays GmbH, an in-vitro diagnostics and automated laboratory products manufacturer in Dahlewitz/Berlin, today introduces its new ELISA system for COVID-19 diagnostics (Anti-SARS-CoV-2 diagnostics).

GA CoV-2 test kits, ELISA based, are particularly suitable for screening large numbers of cases and thus for the rapid determination of the immune status after a possible exposure to SARS-CoV-2. The status of the individual immune system after a disease is quickly and reliably detected with the GA CoV-2 Test Kit by determining the specific immunoglobulins IgM and IgG in the blood of potentially previously infected patients.

SARS-CoV-2 belongs to the *betacoronavirus* group, the same group which also encompasses SARS-CoV (2003) and MERS-CoV (2012) belong to. First identified in a respiratory disease outbreak in Wuhan City, Hubei Province, China, SARS-CoV-2 is responsible for the current global pandemic. As with all coronaviruses, the genome of SARS-CoV-2 encodes the spike protein, the envelope protein, the membrane protein and the nucleocapsid protein.

Patients infected with the SARS-CoV-2 may show a wide range of symptoms. In the mild form of COVID-19, the symptoms are similar to those of a cold/flu, while in severe cases, developing pneumonia of both lungs can lead to death of the patient.

Reliable determination of a SARS-CoV-2 infection by patient screening is an essential component to identify the individual immune status, to control the existing pandemic and to reduce the spread of SARS-CoV-2 by targeted measures.

We are proud to be able to provide reliable COVID-19 diagnostics with our GA CoV-2 test kits developed, produced in Europe and shipped from our German distribution centre to international healthcare organizations.